Anti-HER2 classes of drugs, such as trastuzumab, pertuzumab, lapatinib, and T-DM1, for HER2-positive breast cancer have been used to treat cancer (Pondé et al., 2018; Stern, 2012). This evidence concerns the gene ERBB2 and breast carcinoma.